Flotufolastat (Posluma) Report issue

Biologics Peptide Imaging Approved FDA

Active Ingredient History

NOW
  • Now

Chemistry

  • SMILES: CC(C)(C)[Si](F)(c1ccc(C(=O)NC[C@@H](NC(=O)CC[C@@H](C(=O)O)N2CCN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC2)C(=O)N[C@H](CCCCNC(=O)CCC(=O)NCCC[C@@H](NC(=O)CC[C@H](NC(=O)N[C@@H](CCC(=O)O)C(=O)O)C(=O)O)C(=O)O)C(=O)O)cc1)C(C)(C)C
  • InChIKey: QMGJNAVROCDAIW-YNVJYXMMSA-N
  • Mol. Mass: 1471.63
  • ALogP: Missing data
  • ChEMBL Molecule:
    flotufolastat  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: No
  • Imaging: 18-fluorine
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Organizations (8)

Research & Development (7)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (1)

Approved Indications (1)


 

Prostatic Neoplasms (approved 2023)

Experimental Indications - Clinical Trial Phases 1-4 (1)


 

Prostatic Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 6
  • # of Trial Organizations: 7

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue